GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally.
GlaxoSmithKline Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹1,468.70|
|52 Week High||₹1,376.00|
|52 Week Low||₹1,767.40|
|1 Month Change||-2.41%|
|3 Month Change||-12.67%|
|1 Year Change||-2.72%|
|3 Year Change||14.68%|
|5 Year Change||0.43%|
|Change since IPO||549.65%|
Recent News & Updates
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
It hasn't been the best quarter for GlaxoSmithKline Pharmaceuticals Limited ( NSE:GLAXO ) shareholders, since the share...
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Is GlaxoSmithKline Pharmaceuticals Limited ( NSE:GLAXO ) a good dividend stock? How can we tell? Dividend paying...
|GLAXO||IN Pharmaceuticals||IN Market|
Return vs Industry: GLAXO underperformed the Indian Pharmaceuticals industry which returned 20% over the past year.
Return vs Market: GLAXO underperformed the Indian Market which returned 63.7% over the past year.
Stable Share Price: GLAXO is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GLAXO's weekly volatility (3%) has been stable over the past year.
About the Company
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, gastrointestinal, nutrition, dermatology, respiratory, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Betnovate, Calpol, Ceftum, and Synflorix brands.
GlaxoSmithKline Pharmaceuticals Fundamentals Summary
|GLAXO fundamental statistics|
Is GLAXO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GLAXO income statement (TTM)|
|Cost of Revenue||₹13.87b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 29, 2021
|Earnings per share (EPS)||21.75|
|Net Profit Margin||11.03%|
How did GLAXO perform over the long term?See historical performance and comparison
2.0%Current Dividend Yield
Is GlaxoSmithKline Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GLAXO (₹1468.7) is trading above our estimate of fair value (₹477.84)
Significantly Below Fair Value: GLAXO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GLAXO is poor value based on its PE Ratio (67.5x) compared to the Indian Pharmaceuticals industry average (24.9x).
PE vs Market: GLAXO is poor value based on its PE Ratio (67.5x) compared to the Indian market (21.5x).
Price to Earnings Growth Ratio
PEG Ratio: GLAXO is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: GLAXO is overvalued based on its PB Ratio (16.6x) compared to the IN Pharmaceuticals industry average (3.1x).
How is GlaxoSmithKline Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLAXO's forecast earnings growth (32% per year) is above the savings rate (6.7%).
Earnings vs Market: GLAXO's earnings (32% per year) are forecast to grow faster than the Indian market (18.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GLAXO's revenue (10.8% per year) is forecast to grow slower than the Indian market (12.8% per year).
High Growth Revenue: GLAXO's revenue (10.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GLAXO's Return on Equity is forecast to be high in 3 years time (38%)
How has GlaxoSmithKline Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GLAXO has a large one-off loss of ₹1.7B impacting its June 30 2021 financial results.
Growing Profit Margin: GLAXO's current net profit margins (11%) are higher than last year (2.9%).
Past Earnings Growth Analysis
Earnings Trend: GLAXO's earnings have declined by 13.1% per year over the past 5 years.
Accelerating Growth: GLAXO's earnings growth over the past year (307.1%) exceeds its 5-year average (-13.1% per year).
Earnings vs Industry: GLAXO earnings growth over the past year (307.1%) exceeded the Pharmaceuticals industry 35.8%.
Return on Equity
High ROE: GLAXO's Return on Equity (24.6%) is considered high.
How is GlaxoSmithKline Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: GLAXO's short term assets (₹22.0B) exceed its short term liabilities (₹13.3B).
Long Term Liabilities: GLAXO's short term assets (₹22.0B) exceed its long term liabilities (₹2.8B).
Debt to Equity History and Analysis
Debt Level: GLAXO's debt to equity ratio (2.3%) is considered satisfactory.
Reducing Debt: GLAXO's debt to equity ratio has increased from 0.1% to 2.3% over the past 5 years.
Debt Coverage: GLAXO's debt is well covered by operating cash flow (1669%).
Interest Coverage: GLAXO earns more interest than it pays, so coverage of interest payments is not a concern.
What is GlaxoSmithKline Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GLAXO's dividend (2.04%) is higher than the bottom 25% of dividend payers in the Indian market (0.34%).
High Dividend: GLAXO's dividend (2.04%) is in the top 25% of dividend payers in the Indian market (1.38%)
Stability and Growth of Payments
Stable Dividend: GLAXO's dividend payments have been volatile in the past 10 years.
Growing Dividend: GLAXO's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (137.9%), GLAXO's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GLAXO's dividends in 3 years are forecast to be covered by earnings (66.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Sridhar Venkatesh serves as Managing Director at GlaxoSmithkline Pharmaceuticals Limited since April 1, 2020. Mr. Venkatesh served as the Commercial Head of Pharmaceuticals at GlaxoSmithkline Pharmaceu...
CEO Compensation Analysis
Compensation vs Market: Sridhar's total compensation ($USD1.10M) is above average for companies of similar size in the Indian market ($USD587.75K).
Compensation vs Earnings: Insufficient data to compare Sridhar's compensation with company performance.
Experienced Management: GLAXO's management team is considered experienced (2.3 years average tenure).
Experienced Board: GLAXO's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
GlaxoSmithKline Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: GlaxoSmithKline Pharmaceuticals Limited
- Ticker: GLAXO
- Exchange: NSEI
- Founded: 1924
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹248.807b
- Shares outstanding: 169.41m
- Website: https://india-pharma.gsk.com
Number of Employees
- GlaxoSmithKline Pharmaceuticals Limited
- GSK House
- Dr. Annie Besant Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 18:03|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.